نتایج جستجو برای: dutasteride

تعداد نتایج: 380  

2013
Irma Margarita Pérez-Rodríguez Martha Elena García-Melendez Kristian Eichelmann Osvaldo Vázquez-Martínez Jorge Ocampo-Candiani

INTRODUCTION Frontal fibrosing alopecia (FFA) is a scarring alopecia characterized by progressive recession of the frontotemporal hairline. Current treatment is aimed at stopping progression, and the combination of dutasteride and pimecrolimus is the most effective therapy. Side effects associated with dutasteride are erectile dysfunction as well as breast tenderness and enlargement, while pime...

2012
AVVNKS Kumar SV Saradhi CB Sekaran TV Reddy Krishna Sunil Kumar

Four simple and sensitive visible spectrophotometric methods have been developed for the assay of dutasteride. Method I describes the interaction of dutasteride, as an n-electron donor, with chloranil, as a pi-acceptor, in acetonitrile to give reddish orange colored chloranil radical anion with absorption maxima at 525 nm. Method II involves the oxidative coupling reaction of dutasteride with 3...

Journal: :The Journal of clinical endocrinology and metabolism 2004
Richard V Clark David J Hermann Glenn R Cunningham Timothy H Wilson Betsy B Morrill Stuart Hobbs

Dihydrotestosterone (DHT) is the primary metabolite of testosterone in the prostate and skin. Testosterone is converted to DHT by 5alpha-reductase, which exists in two isoenzyme forms (types 1 and 2). DHT is associated with development of benign prostatic hyperplasia (BPH), and reduction in its level with 5alpha-reductase inhibitors improves the symptoms associated with BPH and reduces the risk...

Journal: :Collegium antropologicum 2014
Indira Radin Mačukat Josip Spanjol Zeljka Crncevič Orlič Marta Zuvič Butorac Marin Marinovič Dora Fučkar Ćupič

Testosterone is converted to dihyrotestosterone by two isoenzymes of 5alpha-reductase. Finasteride and dutasteride are 5alpha-reductase inhibitors commonly used in the treatment of benign prostatic hyperplasia. We compared indices of bone mineral density in 50 men treated with finasteride, 50 men treated with dutasteride and 50 men as control. Bone mineral density of spine and hip were measured...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2006
Yi Xu Susan L Dalrymple Robyn E Becker Samuel R Denmeade John T Isaacs

PURPOSE Prostatic dihydrotestosterone (DHT) concentration is regulated by precursors from systemic circulation and prostatic enzymes of androgen metabolism, particularly 5alpha-reductases (i.e., SRD5A1 and SRD5A2). Therefore, the levels of expression SRD5A1 and SRD5A2 and the antiprostatic cancer growth response to finasteride, a selective SRD5A2 inhibitor, versus the dual SRD5A1 and SRD5A2 inh...

2011
Robert J Hamilton Stephen J Freedland

With the lifetime risk of being diagnosed with prostate cancer so great, an effective chemopreventive agent could have a profound impact on the lives of men. Despite decades of searching for such an agent, physicians still do not have an approved drug to offer their patients. In this article, we outline current strategies for preventing prostate cancer in general, with a focus on the 5-α-reduct...

Journal: :The Journal of urology 2013
Robert L Grubb Gerald L Andriole Matthew C Somerville Chrysa Mahoney Michael J Manyak Ramiro Castro

PURPOSE The primary objective of the REDUCE (REduction by DUtasteride of prostate Cancer Events) Follow-Up Study was to collect data on the occurrence of newly diagnosed prostate cancers for 2 years beyond the 4-year REDUCE study. MATERIALS AND METHODS The 4-year REDUCE study evaluated prostate cancer risk reduction in men taking dutasteride. This 2-year observational study followed men from ...

2013
Rickvinder Besla Natalie Venier Alexandra Colquhoun Neil E. Fleshner Laurence H. Klotz Vasundara Venkateswaran

Prostate cancer (PCa) is the second most prevalent cancer in men after lung cancer. Prostate cancer development and progression is associated with the dysregulation of a number of molecular pathways; hence, therapeutic strategies targeting such pathways bring great promise. Recently we have shown that metformin, the anti-diabetic drug, can inhibit tumor progression when combined with dutasterid...

Journal: :JAMA 2012
Shalender Bhasin Thomas G Travison Thomas W Storer Kishore Lakshman Manas Kaushik Norman A Mazer Ahn-Hoa Ngyuen Maithili N Davda Hernan Jara Adam Aakil Stephan Anderson Philip E Knapp Samson Hanka Nurahmed Mohammed Pierre Daou Renee Miciek Jagadish Ulloor Anqi Zhang Brad Brooks Katie Orwoll Leife Hede-Brierley Richard Eder Ayan Elmi Geeta Bhasin Lauren Collins Ravinder Singh Shehzad Basaria

CONTEXT Steroid 5α-reductase inhibitors are used to treat benign prostatic hyperplasia and androgenic alopecia, but the role of 5α-dihydrotestosterone (DHT) in mediating testosterone's effects on muscle, sexual function, erythropoiesis, and other androgen-dependent processes remains poorly understood. OBJECTIVE To determine whether testosterone's effects on muscle mass, strength, sexual funct...

2015
Rita Upreti Gregorio Naredo Abdullah M.M. Faqehi Katherine A. Hughes Laurence H. Stewart Brian R. Walker Natalie Z.M. Homer Ruth Andrew

Benign prostatic hyperplasia and prostate cancer can be treated with the 5α-reductase inhibitors, finasteride and dutasteride, when pharmacodynamic biomarkers are useful in assessing response. A novel method was developed to measure the substrates and products of 5α-reductases (testosterone, 5α-dihydrotestosterone (DHT), androstenedione) and finasteride and dutasteride simultaneously by liquid ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید